These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17101210)

  • 1. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
    Hansel W; Enright F; Leuschner C
    Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting breast and prostate cancers through their hormone receptors.
    Leuschner C; Hansel W
    Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
    Hansel W; Leuschner C; Enright F
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
    Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
    Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
    Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
    Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
    Gawronska B; Leuschner C; Enright FM; Hansel W
    Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
    Leuschner C; Enright FM; Gawronska B; Hansel W
    Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
    Hansel W; Leuschner C; Gawrońska B; Enright F
    Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
    Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
    Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.
    Jia L; Noker PE; Piazza GA; Leuschner C; Hansel W; Gorman GS; Coward LU; Tomaszewski J
    J Pharm Pharmacol; 2008 Nov; 60(11):1441-8. PubMed ID: 18957164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
    Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.
    Leuschner C; Kumar CS; Hansel W; Soboyejo W; Zhou J; Hormes J
    Breast Cancer Res Treat; 2006 Sep; 99(2):163-76. PubMed ID: 16752077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.
    Vuorenoja S; Mohanty BP; Arola J; Huhtaniemi I; Toppari J; Rahman NA
    Endocr Relat Cancer; 2009 Jun; 16(2):549-64. PubMed ID: 19261682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.
    Bodek G; Vierre S; Rivero-Müller A; Huhtaniemi I; Ziecik AJ; Rahman NA
    Neoplasia; 2005 May; 7(5):497-508. PubMed ID: 15967102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C mice.
    Bogacki M; Enright FM; Todd WJ; Hansel W
    Reprod Biol; 2008 Jul; 8(2):135-47. PubMed ID: 18677401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate.
    Bodek G; Rahman NA; Zaleska M; Soliymani R; Lankinen H; Hansel W; Huhtaniemi I; Ziecik AJ
    Breast Cancer Res Treat; 2003 May; 79(1):1-10. PubMed ID: 12779076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors.
    Leuschner C; Enright FM; Melrose PA; Hansel W
    Prostate; 2001 Feb; 46(2):116-25. PubMed ID: 11170139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
    Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
    Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.